American Capital Management Inc. Has $89.07 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)

American Capital Management Inc. lifted its holdings in shares of Bio-Techne Co. (NASDAQ:TECH - Free Report) by 2.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,114,393 shares of the biotechnology company's stock after purchasing an additional 27,508 shares during the quarter. Bio-Techne accounts for approximately 2.9% of American Capital Management Inc.'s portfolio, making the stock its 10th largest position. American Capital Management Inc. owned about 0.70% of Bio-Techne worth $89,073,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Suvretta Capital Management LLC purchased a new position in Bio-Techne in the third quarter worth $208,000. Hantz Financial Services Inc. boosted its holdings in shares of Bio-Techne by 6.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 13,960 shares of the biotechnology company's stock worth $1,116,000 after purchasing an additional 834 shares in the last quarter. PEAK6 Investments LLC bought a new position in shares of Bio-Techne during the 3rd quarter valued at about $698,000. Public Sector Pension Investment Board increased its position in shares of Bio-Techne by 11.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 6,830 shares of the biotechnology company's stock valued at $546,000 after purchasing an additional 700 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Bio-Techne by 2.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 754,344 shares of the biotechnology company's stock worth $60,295,000 after purchasing an additional 20,277 shares during the last quarter. 98.95% of the stock is currently owned by institutional investors.

Bio-Techne Stock Down 0.0 %

NASDAQ:TECH traded down $0.02 on Friday, reaching $75.36. 464,410 shares of the stock traded hands, compared to its average volume of 1,041,467. The company's fifty day simple moving average is $73.57 and its 200 day simple moving average is $74.97. The company has a market capitalization of $11.97 billion, a price-to-earnings ratio of 80.17, a PEG ratio of 5.50 and a beta of 1.28. Bio-Techne Co. has a 12 month low of $61.16 and a 12 month high of $85.57. The company has a current ratio of 4.56, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.04. The company had revenue of $289.46 million during the quarter, compared to analyst estimates of $280.22 million. Bio-Techne had a net margin of 12.86% and a return on equity of 12.76%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.35 EPS. Equities analysts predict that Bio-Techne Co. will post 1.68 EPS for the current fiscal year.

Bio-Techne Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 22nd. Investors of record on Monday, November 11th were issued a $0.08 dividend. The ex-dividend date of this dividend was Friday, November 8th. This represents a $0.32 annualized dividend and a yield of 0.42%. Bio-Techne's payout ratio is 34.04%.

Analyst Ratings Changes

Several brokerages have recently issued reports on TECH. Benchmark restated a "buy" rating and issued a $95.00 target price on shares of Bio-Techne in a report on Tuesday, August 13th. Robert W. Baird increased their price target on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. Royal Bank of Canada cut their price objective on Bio-Techne from $72.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Thursday, August 8th. StockNews.com upgraded Bio-Techne from a "hold" rating to a "buy" rating in a research report on Tuesday, November 12th. Finally, Scotiabank boosted their price objective on shares of Bio-Techne from $83.00 to $88.00 and gave the stock a "sector outperform" rating in a research note on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $81.78.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.